Tocilizumab and other targeted therapies for severe cutaneous immune‐related adverse events
Linked Article: Hibler and Markova. Br J Dermatol 2020; 183:785–787.
Gespeichert in:
| Veröffentlicht in: | British journal of dermatology (1951) 2020-10, Vol.183 (4), p.613-613 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 613 |
|---|---|
| container_issue | 4 |
| container_start_page | 613 |
| container_title | British journal of dermatology (1951) |
| container_volume | 183 |
| creator | Thompson, L.L. Chen, S.T. |
| description | Linked Article: Hibler and Markova. Br J Dermatol 2020; 183:785–787. |
| doi_str_mv | 10.1111/bjd.19322 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2448222845</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2448222845</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3532-9b61a6e6b502d46b3497a2f4153def9a5afbb94a3b3ce6aa6fbb8a71e75f817a3</originalsourceid><addsrcrecordid>eNp10M1Kw0AQB_BFFFurB19AFjx5SLsf2U1y1PqN4KUeJcwmE01pkrqbKPXkI_iMPolbU705l2Hgx3_gT8ghZ2PuZ2Lm-ZgnUogtMuRSq0BwKbfJkDEWBSzRckD2nJszxiVTbJcMpIgTIXU4JI-zJisX5XtXgaFQ57Rpn9HSFuwTtpjT9QXLEh0tGksdvqJFmnUt1Nh0jpZV1dX49fFpcQFrD7kXDqmHdev2yU4BC4cHmz0iD5cXs-l1cHd_dTM9vQsyqaQIEqM5aNRGMZGH2sgwiUAUIVcyxyIBBYUxSQjSyAw1gPZnDBHHSBUxj0COyHGfu7TNS4euTedNZ2v_MhVhGAsh4lB5ddKrzDbOWSzSpS0rsKuUs3RdZOqLTH-K9PZok9iZCvM_-ducB5MevJULXP2flJ7dnveR37rKfys</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2448222845</pqid></control><display><type>article</type><title>Tocilizumab and other targeted therapies for severe cutaneous immune‐related adverse events</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Thompson, L.L. ; Chen, S.T.</creator><creatorcontrib>Thompson, L.L. ; Chen, S.T.</creatorcontrib><description>Linked Article: Hibler and Markova. Br J Dermatol 2020; 183:785–787.</description><identifier>ISSN: 0007-0963</identifier><identifier>EISSN: 1365-2133</identifier><identifier>DOI: 10.1111/bjd.19322</identifier><identifier>PMID: 32892364</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized - adverse effects ; Humans ; Immunosuppressive agents ; Monoclonal antibodies</subject><ispartof>British journal of dermatology (1951), 2020-10, Vol.183 (4), p.613-613</ispartof><rights>2020 British Association of Dermatologists</rights><rights>Copyright © 2020 British Association of Dermatologists</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3532-9b61a6e6b502d46b3497a2f4153def9a5afbb94a3b3ce6aa6fbb8a71e75f817a3</citedby><cites>FETCH-LOGICAL-c3532-9b61a6e6b502d46b3497a2f4153def9a5afbb94a3b3ce6aa6fbb8a71e75f817a3</cites><orcidid>0000-0001-8844-3284</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjd.19322$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjd.19322$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32892364$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thompson, L.L.</creatorcontrib><creatorcontrib>Chen, S.T.</creatorcontrib><title>Tocilizumab and other targeted therapies for severe cutaneous immune‐related adverse events</title><title>British journal of dermatology (1951)</title><addtitle>Br J Dermatol</addtitle><description>Linked Article: Hibler and Markova. Br J Dermatol 2020; 183:785–787.</description><subject>Antibodies, Monoclonal</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Humans</subject><subject>Immunosuppressive agents</subject><subject>Monoclonal antibodies</subject><issn>0007-0963</issn><issn>1365-2133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10M1Kw0AQB_BFFFurB19AFjx5SLsf2U1y1PqN4KUeJcwmE01pkrqbKPXkI_iMPolbU705l2Hgx3_gT8ghZ2PuZ2Lm-ZgnUogtMuRSq0BwKbfJkDEWBSzRckD2nJszxiVTbJcMpIgTIXU4JI-zJisX5XtXgaFQ57Rpn9HSFuwTtpjT9QXLEh0tGksdvqJFmnUt1Nh0jpZV1dX49fFpcQFrD7kXDqmHdev2yU4BC4cHmz0iD5cXs-l1cHd_dTM9vQsyqaQIEqM5aNRGMZGH2sgwiUAUIVcyxyIBBYUxSQjSyAw1gPZnDBHHSBUxj0COyHGfu7TNS4euTedNZ2v_MhVhGAsh4lB5ddKrzDbOWSzSpS0rsKuUs3RdZOqLTH-K9PZok9iZCvM_-ducB5MevJULXP2flJ7dnveR37rKfys</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Thompson, L.L.</creator><creator>Chen, S.T.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0000-0001-8844-3284</orcidid></search><sort><creationdate>202010</creationdate><title>Tocilizumab and other targeted therapies for severe cutaneous immune‐related adverse events</title><author>Thompson, L.L. ; Chen, S.T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3532-9b61a6e6b502d46b3497a2f4153def9a5afbb94a3b3ce6aa6fbb8a71e75f817a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibodies, Monoclonal</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Humans</topic><topic>Immunosuppressive agents</topic><topic>Monoclonal antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thompson, L.L.</creatorcontrib><creatorcontrib>Chen, S.T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>British journal of dermatology (1951)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thompson, L.L.</au><au>Chen, S.T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tocilizumab and other targeted therapies for severe cutaneous immune‐related adverse events</atitle><jtitle>British journal of dermatology (1951)</jtitle><addtitle>Br J Dermatol</addtitle><date>2020-10</date><risdate>2020</risdate><volume>183</volume><issue>4</issue><spage>613</spage><epage>613</epage><pages>613-613</pages><issn>0007-0963</issn><eissn>1365-2133</eissn><abstract>Linked Article: Hibler and Markova. Br J Dermatol 2020; 183:785–787.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>32892364</pmid><doi>10.1111/bjd.19322</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0001-8844-3284</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0963 |
| ispartof | British journal of dermatology (1951), 2020-10, Vol.183 (4), p.613-613 |
| issn | 0007-0963 1365-2133 |
| language | eng |
| recordid | cdi_proquest_journals_2448222845 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Antibodies, Monoclonal Antibodies, Monoclonal, Humanized - adverse effects Humans Immunosuppressive agents Monoclonal antibodies |
| title | Tocilizumab and other targeted therapies for severe cutaneous immune‐related adverse events |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T07%3A42%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tocilizumab%20and%20other%20targeted%20therapies%20for%20severe%20cutaneous%20immune%E2%80%90related%20adverse%20events&rft.jtitle=British%20journal%20of%20dermatology%20(1951)&rft.au=Thompson,%20L.L.&rft.date=2020-10&rft.volume=183&rft.issue=4&rft.spage=613&rft.epage=613&rft.pages=613-613&rft.issn=0007-0963&rft.eissn=1365-2133&rft_id=info:doi/10.1111/bjd.19322&rft_dat=%3Cproquest_cross%3E2448222845%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2448222845&rft_id=info:pmid/32892364&rfr_iscdi=true |